196 related articles for article (PubMed ID: 36721173)
41. TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
Xin H; Zhang C; Ding Z; Zhang M; Ding G; Li N
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101777. PubMed ID: 34333197
[No Abstract] [Full Text] [Related]
42. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
43. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
44. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
[TBL] [Abstract][Full Text] [Related]
45. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report.
Takahashi K; Kim J; Takahashi A; Hashimoto S; Doi M; Furuya K; Hashimoto R; Owada Y; Ogawa K; Ohara Y; Akashi Y; Hisakura K; Enomoto T; Shimomura O; Noguchi M; Oda T
World J Hepatol; 2021 Mar; 13(3):384-392. PubMed ID: 33815680
[TBL] [Abstract][Full Text] [Related]
46. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
48. Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma.
Kuwano A; Yada M; Koga Y; Tanaka K; Ohishi Y; Masumoto A; Motomura K
Oncol Lett; 2024 Jul; 28(1):309. PubMed ID: 38784605
[TBL] [Abstract][Full Text] [Related]
49. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.
Endo K; Kuroda H; Abe T; Sato H; Kooka Y; Oikawa T; Sato A; Nishiya M; Sugai T; Takikawa Y
Hepatol Res; 2021 Oct; 51(10):1082-1086. PubMed ID: 33982336
[TBL] [Abstract][Full Text] [Related]
50. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.
Yi Y; Sun BY; Weng JL; Zhou C; Zhou CH; Cai MH; Zhang JY; Gao H; Sun J; Zhou J; Fan J; Ren N; Qiu SJ
Front Oncol; 2022; 12():1046584. PubMed ID: 36505772
[TBL] [Abstract][Full Text] [Related]
51. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.
Ohya Y; Hayashida S; Tsuji A; Kuramoto K; Shibata H; Setoyama H; Hayashi H; Kuriwaki K; Sasaki M; Iizaka M; Nakahara O; Inomata Y
Surg Case Rep; 2020 Dec; 6(1):318. PubMed ID: 33301055
[TBL] [Abstract][Full Text] [Related]
52. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
53. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.
Lau WY; Lai EC
Ann Surg Oncol; 2007 Dec; 14(12):3301-9. PubMed ID: 17891443
[TBL] [Abstract][Full Text] [Related]
54. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
[TBL] [Abstract][Full Text] [Related]
55. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
56. Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment.
Chen D; Chen X; Xu L; Wang Y; Zhu L; Kang M
Neoplasma; 2023 Aug; 70(4):580-587. PubMed ID: 37789782
[TBL] [Abstract][Full Text] [Related]
57. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
58. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
Sano S; Asahi Y; Kamiyama T; Kakisaka T; Orimo T; Nagatsu A; Aiyama T; Kazui K; Shomura H; Ueki S; Sakamoto Y; Shirakawa C; Kamachi H; Sugino H; Mitsuhashi T; Taketomi A
Int Cancer Conf J; 2023 Jan; 12(1):7-13. PubMed ID: 36605836
[TBL] [Abstract][Full Text] [Related]
59. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
60. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]